Combating coxsackievirus B infections. - Université de Lille Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Reviews in Medical Virology Année : 2022

Combating coxsackievirus B infections.


Coxsackieviruses B (CVB) are small, non-enveloped, single-stranded RNA viruses belonging to the Enterovirus genus of the Picornaviridae family. They are common worldwide and cause a wide variety of human diseases ranging from those having relatively mild symptoms to severe acute and chronic pathologies such as cardiomyopathy and type 1 diabetes. The development of safe and effective strategies to combat these viruses remains a challenge. The present review outlines current approaches to control CVB infections and associated diseases. Various drugs targeting viral or host proteins involved in viral replication as well as vaccines have been developed and shown potential to prevent or combat CVB infections in vitro and in vivo in animal models. Repurposed drugs and alternative strategies targeting miRNAs or based on plant extracts and probiotics and their derivatives have also shown antiviral effects against CVB. In addition, clinical trials with vaccines and drugs are underway and offer hope for the prevention or treatment of CVB-induced diseases.


Fichier non déposé

Dates et versions

hal-04448620 , version 1 (09-02-2024)



Abdulaziz Alhazmi, Magloire Pandoua Nekoua, Ambroise Mercier, Ines Vergez, Famara Sane, et al.. Combating coxsackievirus B infections.. Reviews in Medical Virology, 2022, Reviews in Medical Virology, 33, pp.e2406. ⟨10.1002/rmv.2406⟩. ⟨hal-04448620⟩


1 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More